|
|
![horizontal rule](https://webarchive.library.unt.edu/web/20090117044026im_/http://www.fda.gov/graphics/blkpixel.gif) |
Congressional
Testimony
|
|
![](https://webarchive.library.unt.edu/web/20090117044026im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
|
|
|
|
![](https://webarchive.library.unt.edu/web/20090117044026im_/http://www.fda.gov/graphics/dot_clear.gif) |
2001
October
- Bernard Schwetz,
D.V.M, Ph.D., October 10, 2001
Acting Principal Deputy Commissioner, Food and Drug Administration,
Committee on Governmental Affairs to discuss the Federal food
safety system and ensuring the safety of the food supply is
a top priority for HHS and the Administration.
September
- John Taylor, September
10, 2001
Director, Office of Enforcement, Office of Regulatory Affairs
before the Special Committee on Aging to discuss health fraud
specifically as it relates to dietary supplements.
- William K. Hubbard,
September 5, 2001
Senior Associate Commissioner for Policy, Planning and Legislation
before the Subcommittee on Consumer Affairs, Foreign Commerce,
and Tourism to discuss our mutual concerns related to the
importation of drugs into the United States.
July
- Nancy M. Ostrove,
Ph.D., July 24, 2001
Deputy Director, Division of Drug Marketing, Advertising and
Communications, Center for Drug Evaluation and Research before
the House Subcommittee on Consumer Affairs, Foreign Commerce,
and Tourism to discuss direct-to-consumer promotion of prescription
drugs.
June
- Robert J.
Temple, M.D., June 20, 2001
Associate Director for Medical Policy, Center for Drug Evaluation
and Research to discuss an important issue of the availability
of investigational drugs for what is commonly referred to
as compassionate use.
- Janet Woodcock, M.D.,
June 13, 2001
Director, Center
for Drug Evaluation and Research-- Subcommittee
on Health
to update you on three important areas that CDER is continuing
to work on.
- William K. Hubbard,
June 7, 2001
Senior Associate Commissioner for Policy, Planning and Legislation
-- Submittee on Oversight and Investigations to discuss our
mutual concerns related to the importation of drugs into the
United States (U.S.).
May
- Kathryn C. Zoon, Ph.D.,
May 24, 2001 Director Center for Biologics Evaluation
and Research (CBER) -- Permanent Subcommittee on Investigations
to discuss the regulation of many of the different types of
human tissue and cells used in transplantation.
- Gary Buehler, RPh,
May 24, 2001
Acting Director of the Office of Generic Drugs, Center for
Drug Evaluation and Research (CDER), --Committee on the Judiciary
to discuss FDA's implementation of provisions of the Drug
Price Competition and Patent Term Restoration Act of 1984
(Hatch-Waxman Amendments) which govern the generic drug approval
process
- Bernard
Schwetz, D.V.M, Ph.D., May 10, 2001
Acting Principal Deputy Commissioner, Food and Drug Administration,
United States Senate, Committee on Appropriations to discuss
some of the accomplishments, as well as the challenges FDA
faces in the new century.
- Janet Woodcock, M.D.,
May 8, 2001
Director, Center for Drug Evaluation and Research-- Committee
on Health, Education, Labor and Pensions to discuss FDA's
role with respect to implementation of the pediatric exclusivity
provisions.
- Linda
Suydam, D.P.A., May 3, 2001
Senior Associate
Commissioner at the Food and Drug Administration--
Committee on Energy
and Commerce to
discuss the Agency's progress and success in implementing
the Food and Drug Administration Modernization Act of 1997
(FDAMA or Modernization Act).
April
- Karen Midthun, M.D., April
24, 2001
Director, Office of Vaccines Research and Review, Center for
Biologics Evaluation and Research-- Before the Committee on
Government Reform to explain FDA's ongoing efforts in response
to the issue of vaccines and autism.
- Stephen Sundlof, D.V.M.,
Ph.D, April 4, 2001
Director, Center for Veterinary Medicine -- Before the Committee
on Commerce, Science, and Transportation to discuss the measures
by the Federal government to prevent bovine sponiform encephalopathy
(BSE) or "Mad Cow Disease" from occurring in the
United States.
March
- Kathryn C. Zoon,
Ph.D., March 28, 2001
Director, Center for Biologics Evaluation and Research
-- Before the Subcommittee on Oversight and Investigations
to discuss FDA's views on the use of cloning technology to
clone a human being as a cause for public health concern.
- Joseph A Levitt, Esq.,
March 20, 2001
Director of the Center for Food Safety and Applied Nutrition/FDA
-- Before the Committee on Government Reform to update you
on FDA's progress in the area of dietary supplements since
I testified before this committee on May 27, 1999.
- Bernard
Schwetz, D.V.M, Ph.D., March 8, 2001
Acting Principal Deputy Commissioner
Food and Drug Administration, United States House of Representatives,
Committee on Appropriations to discuss some of the accomplishments,
as well as the challenges FDA faces in the new century.
|
![](https://webarchive.library.unt.edu/web/20090117044026im_/http://www.fda.gov/graphics/dot_clear.gif) |
![](https://webarchive.library.unt.edu/web/20090117044026im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
![](https://webarchive.library.unt.edu/web/20090117044026im_/http://www.fda.gov/graphics/dot_clear.gif) |
![](https://webarchive.library.unt.edu/web/20090117044026im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
![](https://webarchive.library.unt.edu/web/20090117044026im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
![](https://webarchive.library.unt.edu/web/20090117044026im_/http://www.fda.gov/graphics/dot_clear.gif) |
|
|
|
|